Paradigm Biopharmaceuticals Limited (ASX: PAR) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Paradigm Biopharmaceuticals Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Paradigm Biopharmaceuticals Limited (ASX: PAR)
Latest News
Share Fallers
Why Domino's, Inghams, Kogan, and Paradigm shares are sinking
Share Gainers
Why AMP, Eclipx, Paradigm, and Praemium shares are surging higher
Share Gainers
Paradigm (ASX:PAR) share price shoots 30% higher on FDA update
Healthcare Shares
Why the Paradigm (ASX:PAR) share price is pushing higher today
Healthcare Shares
The Paradigm (ASX:PAR) share price is up 11% on Tuesday
Share Fallers
Why Limeade, Paradigm, Sandfire, & Vita shares are falling
Share Fallers
Paradigm (ASX:PAR) share price sinks 8% on FDA update
Share Market News
Why the Paradigm (ASX:PAR) share price is lifting today
Share Fallers
Why Bubs, Mayne Pharma, Paradigm, & PointsBet shares are tumbling lower
Share Fallers
Why the Paradigm (ASX:PAR) share price is sinking 14% on Tuesday
Broker Notes
Top brokers name 3 ASX shares to sell next week
Share Gainers
Why Life360, Paradigm, Sayona Mining, & Telstra shares are charging higher
Frequently Asked Questions
-
No, Paradigm does not pay shareholder dividends at this time.
-
Paradigm Biopharmaceuticals Limited listed on the ASX on 19 August 2015.
PAR ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Paradigm Biopharmaceuticals Limited
Paradigm Biopharmaceuticals Ltd (ASX: PAR) is a late-stage drug development company researching drug repurposing. The company seeks to identify and transform existing molecules to develop effective treatments for conditions with limited treatment options. Currently, more than 30% of therapies approved or launched globally represent drugs approved for new indications, reformulations, or new combinations of existing drugs.
Paradigm's current commercial prospect is injectable pentosan polysulfate sodium (PPS, or brand name Zilosul®) in the treatment of osteoarthritis. PPS is FDA-approved and has a track record of treating inflammation including bladder condition cystitis and is used in the EU for preventing deep vein thrombosis. Paradigm has advanced to Phase 3 trial stage investigating PPS for osteoarthritis treatment. The company is based in Melbourne with offices in the US and Europe.
